HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models

Multiple myeloma remains largely incurable due to refractory disease; therefore, novel treatment strategies that are safe and well-tolerated are required. Here, we studied the modified herpes simplex virus HSV1716 (SEPREHVIR(®)), which only replicates in transformed cells. Myeloma cell lines and pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazzyman, Simon, Stewart, Georgia R., Yeomans, James, Linford, Adam, Lath, Darren, Conner, Joe, Muthana, Munitta, Chantry, Andrew D., Lawson, Michelle A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059747/
https://www.ncbi.nlm.nih.gov/pubmed/36992311
http://dx.doi.org/10.3390/v15030603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059747/
https://www.ncbi.nlm.nih.gov/pubmed/36992311
http://dx.doi.org/10.3390/v15030603

Ejemplares similares